Prostate Cancer

Prostate Cancer

Newly Diagnosed Prostate Cancer

Radical Prostatectomy

PROTEUS: A Study of ERLEADA (Apalutamide) in Participants With High‑Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Phase: 3
Study Product: Apalutamide with ADT vs. ADT with placebo
Estimated Study Completion Date: April 22, 2024
ClinicalTrials.gov Identifier: NCT03767244


Radiation Therapy

PrTK03: A Randomized Controlled Trial of Prostatak® As Adjuvant To Upfront Radiation Therapy for Localized Prostate Cancer

Phase: 3
Study Product: ProstAtak + valacyclovir adjuvant to up-front radiation therapy vs. placebo + valacyclovir adjuvant to up-front radiation therapy
Estimated Study Completion Date: December 2022
ClinicalTrials.gov Identifier: NCT01436968


PSA Relapse

MAP: Muscadine Plus (MPX) In Men With Prostate Cancer

Phase: 3
Study Product: Muscadine Plus
Estimated Study Completion Date: December 2021
ClinicalTrials.gov Identifier: NCT03535675


RhoVac-002: A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy For Localized Prostate Cancer

Phase: 2
Study Product: RV001V
Estimated Study Completion Date: September 2022
ClinicalTrials.gov Identifier: NCT04114825

MCSPC

KEYNOTE-991: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Phase: 3
Study Product: pembrolizumab plus enzalutamide plus ADT vs. placebo plus enzalutamide plus ADT
Estimated Study Completion Date: September 1, 2026
ClinicalTrials.gov Identifier: NCT04191096


CAPItello-281: A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with DeNovo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281)

Phase: 3
Study Product: Capivasertib plus abiraterone vs. placebo plus abiraterone
Estimated Study Completion Date: November 2025
ClinicalTrials.gov Identifier: NCT04493853


 

MCSPC or MCRPC

Responding to Abiraterone

MVY-601-049: A Phase 1, Open-Label, Single-Cohort Safety and Tolerability Study of Relugolix in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Castration-Sensitive Prostate Cancer or Metastatic Castration-Resistant Prostate Cancer Being Treated with Standard-of-Care Leuprolide and Abiraterone plus Prednisone

Phase: 1
Study Product: Relugolix + Abiraterone
Estimated Study Completion Date: December 2021
ClinicalTrials.gov Identifier: NCT04666129


Progressing on Abiraterone Acetate

DisperSol: A PK and Dose Escalation and Expansion Study of DST-2970 in Patients With Prostate Cancer With Rising PSA on Treatment With Abiraterone Acetate

Phase: 1
Study Product: Abiraterone Acetate plus Prednisone 5Mg Tab plus DST-2970 (Abiraterone)
Estimated Study Completion Date: July 31, 2022
ClinicalTrials.gov Identifier: NCT04291664


nmCRPC or MCRPC

DaroAct 20609: Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)

Phase: 2b
Study Product: Darolutamide vs. Enzalutamide
Estimated Study Completion Date: December 31, 2022
ClinicalTrials.gov Identifier: NCT04157088


mCRPC

Treatment naïve

MAGNITUDE: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

Phase: 3
Study Product: Niraparib with Abiraterone Acetate and Prednisone vs. Placebo with Abiraterone Acetate and Prednisone
Estimated Study Completion Date: July 21, 2022
ClinicalTrials.gov Identifier: NCT03748641


TALAPRO-2: Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

Phase: 3
Study Product: Talazoparib with Enzalutamide vs. Placebo with Enzalutamide
Estimated Study Completion Date: November 25, 2024
ClinicalTrials.gov Identifier: NCT03395197


ESCALATE: Enzalutamide or Darolutamide (1:1) 12 week run-in then add Radium-223

Phase: 3
Study Product: Enzalutamide vs. Darolutamide with Radium-223
Estimated Study Completion Date: September 2024
ClinicalTrials.gov Identifier: NCT04237584


Treatment naïve or post NHA

 


Post Abi, Enza, and/or Apa

Post Abi or Enza or Apa

KEYNOTE-921: Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Phase: 3
Study Product: Pembrolizumab with Docetaxel vs. Placebo with Docetaxel
Estimated Study Completion Date: February 28, 2023
ClinicalTrials.gov Identifier: NCT03834506


KEYNOTE-641: Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer

Phase: 3
Study Product: Pembrolizumab with Enzalutamide vs. Placebo with Enzalutamide
Estimated Study Completion Date: November 12, 2023
ClinicalTrials.gov Identifier: NCT03834493


Docetaxel Candidate

BMS CA209-7DX: Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer 

Phase: 3
Study Product: Nivolumab + Docetaxel Vs. Placebo + Docetaxel
Estimated Study Completion Date: July 6, 2024
ClinicalTrials.gov Identifier: NCT04100018


Post Chemotherapy

KEYLYNK-010: Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Phase: 3
Study Product: Pembrolizumab with Olaparib vs. Abiraterone Acetate or Enzalutamide
Estimated Study Completion Date: September 30, 2022
ClinicalTrials.gov Identifier: NCT03834519


GO27983: Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Phase: 2
Study Product: Ipatasertib
Estimated Study Completion Date: April 30, 2021
ClinicalTrials.gov Identifier: NCT01485861


Progressing on NHA (Abi or Enza)

ORIC-101-02: An Open-Label Phase 1b Study of ORIC-101 in Combination With Enzalutamide in Patients With Metastatic Prostate Cancer Progressing on Enzalutamide

Phase: 1b
Study Product: ORIC-101 vs. Enzalutamide
Estimated Study Completion Date: December 2022
ClinicalTrials.gov Identifier: NCT04033328


PLX124-04: A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase: 1b/2a
Study Product: PLX2853 + Abiraterone Acetate & Prednisone versus PLX2853 + Olaparib
Estimated Study Completion Date: March 30, 2023
ClinicalTrials.gov Identifier: NCT04556617


DST-2970-104: A Phase 1 PK and Dose Escalation and Expansion Study of DST-2970 in Patients With Prostate Cancer With Rising PSA on Treatment With Abiraterone Acetate

Phase: 1
Study Product: DST-2970
Estimated Study Completion Date: July 31, 2022
ClinicalTrials.gov Identifier: NCT04291664


Post Abi and/or Enza

Pfizer c2321001: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Phase: 1
Study Product: PF-06821497
Estimated Study Completion Date: October 13, 2021
ClinicalTrials.gov Identifier: NCT03460977


AZ D5339C00001: A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)

Phase: 2a
Study Product: Ceralasertib
Estimated Study Completion Date: June 8, 2023
ClinicalTrials.gov Identifier: NCT04564027


Post Abi, Enza, Apa, and/or Daro

FORMA 7051-ONC-101: A Phase 1 Study of FT-7051 in Men with Metastatic Castration-Resistant Prostate Cancer 

Phase: 1
Study Product: FT-7051
Estimated Study Completion Date: July 2023
ClinicalTrials.gov Identifier: NCT04575766

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember to talk to your healthcare providers first before making decisions about your plan of care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study. To learn more about our trials, call Jennifer at (843) 449-1010 ext. 316 or email us by filling out the form below.


Please fill in the form below to email us to learn more about our trials: